<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">HATA, AKITO</style></author><author><style face="normal" font="default" size="100%">KATAKAMI, NOBUYUKI</style></author><author><style face="normal" font="default" size="100%">NANJO, SHIGEKI</style></author><author><style face="normal" font="default" size="100%">OKUDA, CHIYUKI</style></author><author><style face="normal" font="default" size="100%">KAJI, REIKO</style></author><author><style face="normal" font="default" size="100%">IMAI, YUKIHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">475-479</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: The aim of the present study was to compare successful rate, failure reasons, and complications among procedures of histological rebiopsy. Patients and Methods: We retrospectively reviewed medical records of histologically rebiopsied cases with non-small cell lung cancer. Results: One hundred and eleven histological rebiopsies were performed in: 86 (77%) lung; 11 (10%) lymph node; 5 (5%) pleura; 4 (4%) liver; 2 (2%) muscle; 2 (2%) adrenal gland; and 1 (1%) rib. Successful rate by computed tomography-guided biopsy (CTGB), transbronchial biopsy (TBB), and ultrasound-guided biopsy were 86% (48/56), 90% (28/31), and 100% (24/24), respectively. Reasons for rebiopsy failure by CTGB were no/insufficient malignant cells (n=5) and pneumothorax (n=3), and those by TBB were no/insufficient malignant cells (n=2) and bleeding (n=1). Severe complications (≥grade 3): one grade 3 pneumothorax and one grade 4 air embolization were observed in two (2%, 2/111) cases receiving CTGB. Conclusion: Rebiopsy of histological samples can be highly successful and feasible by optimal procedural selection.</style></abstract></record></records></xml>